Literature DB >> 10547276

Increased monocyte MCP-1 production in acute alcoholic hepatitis.

M N Devalaraja1, C J Mcclain, S Barve, K Vaddi, D B Hill.   

Abstract

Monocyte chemoattractant protein-1 (MCP-1) is a potent mononuclear cell-specific chemotactic protein. MCP-1 is a candidate chemoattractant for activation and hepatic infiltration of mononuclear cells in alcoholic hepatitis (AH). Blood was collected from 15 patients with AH (mean bilirubin 17.6+/-3.5 mg/dl; normal 0. 2-1.0 mg/dl) on admission and at time points for up to 6 months. Peripheral blood monocytes were isolated and MCP-1 production assessed by measuring MCP-1 concentrations in monocyte culture supernatants after overnight (20 h) incubation. Monocytes from normal subjects did not product detectable MCP-1 unless stimulated with endotoxin (LPS;5 microg/ml). The mean level of constitutive MCP-1 from AH patient monocytes was 4694+/-2432 pg/ml 20 h on admission. The mean MCP-1 level for LPS-treated monocytes was 4903+/-1540 pg/ml 20 h for normal subjects and was significantly elevated in AH patients to 11589+/-3266 pg/ml/20 h. AH patient monocyte MCP-1 production was decreased in vitro when monocytes were treated with N-acetylcysteine (5 mM) and also decreased over the 6-month study as the patients improved clinically. MCP-1 plasma levels were below the detection limits of the assay used in both AH patients and normal subjects. Thus, monocytes from AH patients not only constitutively product MCP-1, but also produce higher levels of MCP-1 with endotoxin stimulation. Further studies are needed to clarify the role of MCP-1 in the activation and hepatic infiltration of mononuclear cells in alcoholic liver disease. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547276     DOI: 10.1006/cyto.1999.0495

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  16 in total

1.  Time course of microglia activation and brain and blood cytokine/chemokine levels following chronic ethanol exposure and protracted withdrawal in rats.

Authors:  Manuel Sanchez-Alavez; William Nguyen; Simone Mori; Derek N Wills; Dennis Otero; Cindy L Ehlers; Bruno Conti
Journal:  Alcohol       Date:  2018-07-17       Impact factor: 2.405

2.  Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers.

Authors:  Matt Cave; Keith Cameron Falkner; Latasha Henry; Brittany Costello; Bonnie Gregory; Craig J McClain
Journal:  J Occup Environ Med       Date:  2011-10       Impact factor: 2.162

Review 3.  Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism.

Authors:  Juliane I Beier; Gavin E Arteel
Journal:  Exp Biol Med (Maywood)       Date:  2012-01

4.  Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative.

Authors:  Jason J Schwartz; Lyska Emerson; Elaine Hillas; Ann Phan; Heather Thiesset; Matthew Firpo; Jeffrey Sorensen; Thomas Kennedy; Mary Rinella
Journal:  Hepatol Int       Date:  2013-02-19       Impact factor: 6.047

Review 5.  Targeting inflammation for the treatment of alcoholic liver disease.

Authors:  Ming-Jiang Xu; Zhou Zhou; Richard Parker; Bin Gao
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

6.  N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study.

Authors:  Luis G Guijarro; Jose Mate; Javier P Gisbert; Jose Luis Perez-Calle; Ignacio Marin-Jimenez; Encarna Arriaza; Tomas Olleros; Mario Delgado; Maria S Castillejo; David Prieto-Merino; Venancio Gonzalez Lara; Amado-Salvador Pena
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

7.  Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutrophil infiltrates.

Authors:  D Degré; A Lemmers; T Gustot; R Ouziel; E Trépo; P Demetter; L Verset; E Quertinmont; V Vercruysse; O Le Moine; J Devière; C Moreno
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 8.  Regulation and functional roles of chemokines in liver diseases.

Authors:  Sheng Cao; Mengfei Liu; Tejasav S Sehrawat; Vijay H Shah
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-11       Impact factor: 73.082

9.  Chronic intermittent ethanol and lipopolysaccharide exposure differentially alter Iba1-derived microglia morphology in the prelimbic cortex and nucleus accumbens core of male Long-Evans rats.

Authors:  Benjamin M Siemsen; Justine D Landin; Jon A McFaddin; Kaylee N Hooker; Lawrence J Chandler; Michael D Scofield
Journal:  J Neurosci Res       Date:  2020-07-03       Impact factor: 4.164

10.  New insights into the role of macrophages in adipose tissue inflammation and Fatty liver disease: modulation by endogenous omega-3 Fatty Acid-derived lipid mediators.

Authors:  Joan Clària; Ana González-Périz; Cristina López-Vicario; Bibiana Rius; Esther Titos
Journal:  Front Immunol       Date:  2011-10-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.